KFDA Approves Extended Pediatric Application of LactiCare-HC

Published: 2005-04-11 06:56:00

Updated: 2005-04-11 06:56:00

Stiefel Korea recently announced that the Korea Food and Drug Administration (KFDA) has given an approval on the extended pediatric application of LactiCare-HC (active ingredient: hydrocortisone) Lotion for the treatment of atopic dermatitis in infants of younger than 2 years old.

According to...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK